KR20250090384A - 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 - Google Patents
근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20250090384A KR20250090384A KR1020257019188A KR20257019188A KR20250090384A KR 20250090384 A KR20250090384 A KR 20250090384A KR 1020257019188 A KR1020257019188 A KR 1020257019188A KR 20257019188 A KR20257019188 A KR 20257019188A KR 20250090384 A KR20250090384 A KR 20250090384A
- Authority
- KR
- South Korea
- Prior art keywords
- antisense oligonucleotide
- dose
- administered
- human subject
- nucleosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779916P | 2018-12-14 | 2018-12-14 | |
| US62/779,916 | 2018-12-14 | ||
| US201962807603P | 2019-02-19 | 2019-02-19 | |
| US62/807,603 | 2019-02-19 | ||
| US201962840879P | 2019-04-30 | 2019-04-30 | |
| US62/840,879 | 2019-04-30 | ||
| PCT/US2019/065936 WO2020123783A1 (en) | 2018-12-14 | 2019-12-12 | Compositions and methods for treating and preventing amyotrophic lateral sclerosis |
| KR1020217020529A KR102821047B1 (ko) | 2018-12-14 | 2019-12-12 | 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217020529A Division KR102821047B1 (ko) | 2018-12-14 | 2019-12-12 | 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250090384A true KR20250090384A (ko) | 2025-06-19 |
Family
ID=69160351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257019188A Pending KR20250090384A (ko) | 2018-12-14 | 2019-12-12 | 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 |
| KR1020217020529A Active KR102821047B1 (ko) | 2018-12-14 | 2019-12-12 | 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217020529A Active KR102821047B1 (ko) | 2018-12-14 | 2019-12-12 | 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220073930A1 (https=) |
| EP (1) | EP3894557A1 (https=) |
| JP (2) | JP7612575B2 (https=) |
| KR (2) | KR20250090384A (https=) |
| CN (3) | CN118987017A (https=) |
| AU (1) | AU2019396522B2 (https=) |
| BR (1) | BR112021011334A2 (https=) |
| CA (1) | CA3115549A1 (https=) |
| CL (1) | CL2021001136A1 (https=) |
| CO (1) | CO2021008187A2 (https=) |
| CR (1) | CR20210384A (https=) |
| IL (1) | IL283833A (https=) |
| JO (1) | JOP20210143A1 (https=) |
| MX (1) | MX2021005086A (https=) |
| MY (1) | MY209775A (https=) |
| PH (1) | PH12021551365A1 (https=) |
| SG (1) | SG11202103415WA (https=) |
| TW (1) | TWI906204B (https=) |
| UY (1) | UY38506A (https=) |
| WO (1) | WO2020123783A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
| CN119679944A (zh) | 2018-01-25 | 2025-03-25 | 渤健马萨诸塞州股份有限公司 | 治疗脊髓性肌萎缩症的方法 |
| US12429487B2 (en) | 2018-12-06 | 2025-09-30 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| BR112023019877A2 (pt) * | 2021-03-31 | 2023-11-07 | Biogen Ma Inc | Tratamento de esclerose lateral amiotrófica |
| WO2025045130A1 (zh) * | 2023-08-29 | 2025-03-06 | 石药集团中奇制药技术（石家庄）有限公司 | 一种抑制sod1基因表达的dsrna分子及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
| EP3119888B1 (en) * | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
| HUE050704T2 (hu) * | 2014-04-01 | 2020-12-28 | Biogen Ma Inc | Összetételek a SOD-1 expressziójának modulálására |
| WO2016077687A1 (en) * | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JP2020518258A (ja) * | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法 |
| WO2018218219A1 (en) * | 2017-05-26 | 2018-11-29 | University Of Miami | Determining onset of amyotrophic lateral sclerosis |
-
2019
- 2019-12-06 TW TW108144617A patent/TWI906204B/zh active
- 2019-12-11 UY UY0001038506A patent/UY38506A/es not_active Application Discontinuation
- 2019-12-12 JP JP2021525191A patent/JP7612575B2/ja active Active
- 2019-12-12 EP EP19836331.9A patent/EP3894557A1/en active Pending
- 2019-12-12 MX MX2021005086A patent/MX2021005086A/es unknown
- 2019-12-12 CR CR20210384A patent/CR20210384A/es unknown
- 2019-12-12 CA CA3115549A patent/CA3115549A1/en active Pending
- 2019-12-12 MY MYPI2021003225A patent/MY209775A/en unknown
- 2019-12-12 CN CN202411184883.6A patent/CN118987017A/zh active Pending
- 2019-12-12 SG SG11202103415WA patent/SG11202103415WA/en unknown
- 2019-12-12 KR KR1020257019188A patent/KR20250090384A/ko active Pending
- 2019-12-12 US US17/291,199 patent/US20220073930A1/en active Pending
- 2019-12-12 AU AU2019396522A patent/AU2019396522B2/en active Active
- 2019-12-12 WO PCT/US2019/065936 patent/WO2020123783A1/en not_active Ceased
- 2019-12-12 KR KR1020217020529A patent/KR102821047B1/ko active Active
- 2019-12-12 CN CN201980080996.2A patent/CN113330116A/zh active Pending
- 2019-12-12 CN CN202411184930.7A patent/CN119185345A/zh active Pending
- 2019-12-12 BR BR112021011334-7A patent/BR112021011334A2/pt unknown
-
2021
- 2021-04-29 CL CL2021001136A patent/CL2021001136A1/es unknown
- 2021-06-09 IL IL283833A patent/IL283833A/en unknown
- 2021-06-09 PH PH12021551365A patent/PH12021551365A1/en unknown
- 2021-06-09 JO JOP/2021/0143A patent/JOP20210143A1/ar unknown
- 2021-06-23 CO CONC2021/0008187A patent/CO2021008187A2/es unknown
-
2024
- 2024-12-06 JP JP2024213950A patent/JP2025023319A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220073930A1 (en) | 2022-03-10 |
| KR20210131992A (ko) | 2021-11-03 |
| MX2021005086A (es) | 2021-08-16 |
| TWI906204B (zh) | 2025-12-01 |
| EP3894557A1 (en) | 2021-10-20 |
| JOP20210143A1 (ar) | 2023-01-30 |
| CN118987017A (zh) | 2024-11-22 |
| UY38506A (es) | 2020-06-30 |
| CN113330116A (zh) | 2021-08-31 |
| JP7612575B2 (ja) | 2025-01-14 |
| TW202035694A (zh) | 2020-10-01 |
| BR112021011334A2 (pt) | 2021-09-08 |
| CA3115549A1 (en) | 2020-06-18 |
| MY209775A (en) | 2025-08-03 |
| CN119185345A (zh) | 2024-12-27 |
| KR102821047B1 (ko) | 2025-06-16 |
| CL2021001136A1 (es) | 2022-01-14 |
| AU2019396522B2 (en) | 2026-04-09 |
| JP2022513597A (ja) | 2022-02-09 |
| CR20210384A (es) | 2021-12-20 |
| SG11202103415WA (en) | 2021-06-29 |
| IL283833A (en) | 2021-07-29 |
| CO2021008187A2 (es) | 2021-09-09 |
| JP2025023319A (ja) | 2025-02-14 |
| WO2020123783A1 (en) | 2020-06-18 |
| PH12021551365A1 (en) | 2021-11-22 |
| AU2019396522A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102821047B1 (ko) | 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법 | |
| US7622455B2 (en) | Methods for slowing familial ALS disease progression | |
| KR20170012207A (ko) | Sod-1 발현을 조절하기 위한 조성물 | |
| KR20210008498A (ko) | Fxi 발현을 감소시키기 위한 화합물 및 방법 | |
| AU2017234678A1 (en) | Methods of modulating KEAP1 | |
| TW201143779A (en) | Dosing regimens for treating and preventing ocular disorders using c-raf antisense | |
| RU2824046C2 (ru) | Составы для лечения и предотвращения бокового амиотрофического склероза | |
| CN117062911A (zh) | 肌萎缩性脊髓侧索硬化症的治疗 | |
| EA051069B1 (ru) | Составы и способы лечения и предотвращения бокового амиотрофического склероза | |
| RU2858547C2 (ru) | Композиции для модулирования экспрессии sod-1 | |
| EP4677089A2 (en) | Compositions and methods for modulating sptlc1 | |
| WO2025136934A1 (en) | Compositions and methods for modulating sptlc2 | |
| WO2020216895A1 (en) | Methods for the treatment of retinal dystrophies by exon-skipping strategy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |